Zealand Pharma and Generate Biomedicines Partner on AI-Engineered…

Event summary

Zealand Pharma and Generate Biomedicines entered a collaboration and license agreement to develop protein therapeutics for metabolic diseases using AI.
Generate will receive $30 million upfront, up to $35 million in early preclinical milestones, and nearly $1.2 billion in total milestones plus tiered royalties for two initial programs.
Zealand Pharma will handle clinical development, regulatory submissions, and worldwide commercialization, while Generate will lead research through lead-candidate selection.
The agreement expands Zealand Pharma’s modality capabilities beyond peptides and extends Generate’s AI platform into obesity and other metabolic diseases.

The big picture

This collaboration marks a significant step in the integration of AI-driven drug discovery with traditional biotech expertise, potentially accelerating the development of next-generation therapeutics for metabolic diseases. The deal size and milestone structure reflect the high stakes and strategic importance of this partnership in an increasingly competitive biotech landscape.

What we're watching

Execution Risk: Whether Zealand Pharma can successfully integrate Generate’s AI platform into its existing pipeline and meet the ambitious milestones.
Market Impact: How this collaboration will position Zealand Pharma and Generate in the competitive landscape of metabolic disease treatments.
Technological Integration: The pace at which AI-engineered protein therapeutics can be developed and brought to market compared to traditional methods.